[4-(2-Fluoro-phenyl)-2-methyl-2H-pyrazol-3-yl]-carbamic acid (R)-1-(2-chloro-phenyl)-ethyl ester;

[4-(2-Fluoro-phenyl)-2-methyl-2H-pyrazol-3-yl]-carbamic acid (S)-1-(2-chloro-phenyl)-ethyl ester;

[4-(2-Fluoro-phenyl)-2-methyl-2H-pyrazol-3-yl]-carbamic acid (R)-1-(3-trifluoromethyl-phenyl)-ethyl ester;

1-{4'-[5-(3-Benzyl-ureido)-1-methyl-1H-pyrazol-4-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; or

1-{4'-[1-Methyl-5-((S)-3-phenyl-butyrylamino)-1H-pyrazol-4-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid.

9. A compound according to any one of claims 1 to 8 for use as a therapeutically active substance.

10. A pharmaceutical composition, comprising a therapeutically effective amount of a compound in accordance with any one of claims 1 to 8 and a therapeutically inert carrier.

11. The use of a compound according to any one of claims 1 to 8 for the treatment or prophylaxis of pulmonary fibrosis.

12. The use of a compound according to any one of claims 1 to 8 for the preparation of a medicament for the treatment or prophylaxis of pulmonary fibrosis.

13. A compound according to any one of claims 1 to 8 for the treatment or prophylaxis of pulmonary fibrosis.

14. A method for the treatment or prophylaxis of pulmonary fibrosis, which method comprises the step of administering an effective amount of a compound as defined in any one of claims 1 to 8 to a patient in need thereof.

~~15. The invention as hereinbefore described.~~